Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a life-sciences company developing a single-molecule proteomics platform designed for large-scale protein analysis, with applications across pharmaceutical, diagnostic, and academic research markets. The company entered the public markets in 2021 through a business combination with an Arya Sciences blank-check vehicle sponsored by Perceptive Advisors, a New York-based healthcare investment firm. An S-1 registration statement associated with the transaction was filed with the SEC on July 22, 2021, under accession number 0001628280-21-014270. Nautilus continues to trade on Nasdaq under the ticker NAUT. Sign up on SpacDesk to access complete filing history, sponsor analytics, and deal-level data on Nautilus and the full de-SPAC universe.